SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-003357 to DYADIC INTERNATIONAL INC (DYAI)

DYADIC INTERNATIONAL INC
Date: March 28, 2025 · CIK: 0001213809 · Accession: 0000000000-25-003357

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286121

Date
March 28, 2025
Author
Division of
Form
UPLOAD
Company
DYADIC INTERNATIONAL INC

Letter

Re: Dyadic International, Inc. Registration Statement on Form S-3 Filed March 26, 2025 File No. 333-286121 Dear Mark Emalfarb:

March 28, 2025

Mark Emalfarb Chief Executive Officer and Director Dyadic International, Inc. 1044 North U.S. Highway One, Suite 201 Jupiter, FL 33477

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jessica Y. Chen, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 28, 2025

Mark Emalfarb
Chief Executive Officer and Director
Dyadic International, Inc.
1044 North U.S. Highway One, Suite 201
Jupiter, FL 33477

 Re: Dyadic International, Inc.
 Registration Statement on Form S-3
 Filed March 26, 2025
 File No. 333-286121
Dear Mark Emalfarb:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jessica Y. Chen, Esq.
</TEXT>
</DOCUMENT>